PFIZER Company Profile

✉ Email this page to a colleague

PFIZER has one hundred and ninety-five approved drugs.

There are forty-nine US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand and twenty-seven patent family members on PFIZER drugs in seventy countries and two hundred and sixty-one supplementary protection certificates in nineteen countries.

International Patents:	1027
US Patents:	49
Tradenames:	159
Ingredients:	130
NDAs:	195
Drug Master File Entries:	3
Patent Litigation for PFIZER:	See patent lawsuits for PFIZER
PTAB Cases with PFIZER as petitioner:	See PTAB cases with PFIZER as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes	11,007,175	⤷ Sign Up				⤷ Sign Up
Pfizer	CORTRIL	hydrocortisone acetate	INJECTABLE;INJECTION	009164-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-005	Jun 20, 2023		RX	Yes	No	8,735,392	⤷ Sign Up	Y	Y		⤷ Sign Up
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	RE47739	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	7,265,221	⤷ Sign Up
Pfizer	COVERA-HS	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020552-002	Feb 26, 1996	5,200,196	⤷ Sign Up
Pfizer	MICRONASE	glyburide	TABLET;ORAL	017498-002	May 1, 1984	3,454,635	⤷ Sign Up
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	6,936,612	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Oral Suspension	100 mg/5 mL	➤ Subscribe	2009-08-03
➤ Subscribe	Injection	2 mg/mL, 100 mL bag	➤ Subscribe	2009-12-29
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2005-12-21
➤ Subscribe	Injection	2 mg/mL, 300 mL bag	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	1 g	➤ Subscribe	2005-08-23
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2170860	36/2020	Austria	⤷ Sign Up	PRODUCT NAME: GLASDEGIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES MALEATSALZES; REGISTRATION NO/DATE: EU/1/20/1451/001 (MITTEILUNG) 20200629
0454511	99C0009	Belgium	⤷ Sign Up	PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
1746999	SPC/GB19/053	United Kingdom	⤷ Sign Up	PRODUCT NAME: DACOMITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS DACOMITINIB MONOHYDRATE; REGISTERED: UK EU/1/19/1354(FOR NI) 20190404; UK PLGB 00057-1677 20190404; UK PLGB 00057-1678 20190404
1470124	132017000046148	Italy	⤷ Sign Up	PRODUCT NAME: PALBOCICLIB, OPZIONALMENTE NELLA FORMA DI UN SALE, ESTERE, AMMIDE O PROFARMACO FARMACEUTICAMENTE ACCETTABILE(IBRANCE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1147/001-006, 20161111
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.